Literature DB >> 33425489

CircMEG3 inhibits telomerase activity by reducing Cbf5 in human liver cancer stem cells.

Xiaoxue Jiang1, Libo Xing1, Yingjie Chen1, Rushi Qin1, Shuting Song1, Yanan Lu1, Sijie Xie1, Liyan Wang1, Hu Pu1, Xin Gui1, Tianming Li1, Jie Xu2, Jiao Li2, Song Jia2, Dongdong Lu1.   

Abstract

Circular RNA (CircRNA) is a newly identified special class of non-coding RNA (ncRNA) that plays an important regulatory role in the progression of certain diseases. Herein, our results indicate that CircMEG3 is downregulated expression and negatively correlated with the expression of telomerase-related gene Cbf5 in human liver cancer. Moreover, CircMEG3 inhibits the growth of human liver cancer stem cells in vivo and in vitro. CircMEG3 inhibits the expression of m6A methyltransferase METTL3 dependent on HULC. Moreover, CircMEG3 inhibits the expression of Cbf5, a component of telomere synthetase H/ACA ribonucleoprotein (RNP; catalyst RNA pseudouracil modification) through METTL3 dependent on HULC. Thereby, CircMEG3 inhibits telomerase activity and shortens telomere lifespan dependent on HULC and Cbf5 in human liver cancer stem cell. Strikingly, increased Cbf5 abrogates the ability of CircMEG3 to inhibit malignant differentiation of human liver cancer stem cells. In summary, these observations provide important basic information for finding effective liver cancer therapeutic targets.
© 2020 The Author(s).

Entities:  

Keywords:  Cbf5; CircMEG3; HULC; METTL3; liver cancer stem cells; telomere

Year:  2020        PMID: 33425489      PMCID: PMC7779543          DOI: 10.1016/j.omtn.2020.11.009

Source DB:  PubMed          Journal:  Mol Ther Nucleic Acids        ISSN: 2162-2531            Impact factor:   8.886


  10 in total

Review 1.  The emerging roles of circRNAs in cancer and oncology.

Authors:  Lasse S Kristensen; Theresa Jakobsen; Henrik Hager; Jørgen Kjems
Journal:  Nat Rev Clin Oncol       Date:  2021-12-15       Impact factor: 66.675

Review 2.  Circular RNAs in hepatocellular carcinoma: Recent advances.

Authors:  Zhao-Shan Niu; Wen-Hong Wang
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

Review 3.  Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer.

Authors:  Xin Huang; Haoyu Guo; Lutong Wang; Lingkai Yang; Zengwu Shao; Weiyue Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-21       Impact factor: 8.886

Review 4.  Mechanism of cancer stemness maintenance in human liver cancer.

Authors:  Ning Liang; Tao Yang; Qian Huang; Pengfei Yu; Chaoxu Liu; Liusheng Chen; Qian Wang; Gang Wang; Xianli He
Journal:  Cell Death Dis       Date:  2022-04-21       Impact factor: 9.685

Review 5.  Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma.

Authors:  Qikuan He; Pengyi Guo; Zhiyuan Bo; Haitao Yu; Jinhuan Yang; Yi Wang; Gang Chen
Journal:  Cancer Cell Int       Date:  2022-08-09       Impact factor: 6.429

6.  circEPSTI1 promotes tumor progression and cisplatin resistance via upregulating MSH2 in cervical cancer.

Authors:  Peng Wu; Jing Qin; Lingyan Liu; Wupeng Tan; Linchen Lei; Jiayu Zhu
Journal:  Aging (Albany NY)       Date:  2022-07-02       Impact factor: 5.955

7.  CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.

Authors:  Kui Luo; Aiqun Liu; Hao Wu; Qiang Liu; Jin Dai; Yu Liu; Zhifei Wang
Journal:  Cell Death Dis       Date:  2022-08-27       Impact factor: 9.685

Review 8.  Long Non-Coding RNA MEG3 in Cellular Stemness.

Authors:  Pei-Fang Hsieh; Cheng-Chia Yu; Pei-Ming Chu; Pei-Ling Hsieh
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

Review 9.  Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions.

Authors:  Xin Wang; Rui Ma; Xilin Zhang; Lian Cui; Yangfeng Ding; Weimin Shi; Chunyuan Guo; Yuling Shi
Journal:  Mol Cancer       Date:  2021-09-24       Impact factor: 27.401

10.  A miR-212-3p/SLC6A1 Regulatory Sub-Network for the Prognosis of Hepatocellular Carcinoma.

Authors:  Dan-Dan Zhang; Wen-Er Wang; Yu-Shui Ma; Yi Shi; Jie Yin; Ji-Bin Liu; Xiao-Li Yang; Rui Xin; Da Fu; Wen-Jie Zhang
Journal:  Cancer Manag Res       Date:  2021-06-28       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.